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Abstract: In this pilot study, we have evaluated bedside diffuse optical monitoring combining
diffuse correlation spectroscopy and near-infrared diffuse optical spectroscopy to assess the effect
of thrombolysis with an intravenous recombinant tissue plasminogen activator (rtPA) on cerebral
hemodynamics in an acute ischemic stroke. Frontal lobes of five patients with an acute middle
cerebral artery occlusion were measured bilaterally during rtPA treatment. Both ipsilesional and
contralesional hemispheres showed significant increases in cerebral blood flow, total hemoglobin
concentration and oxy-hemoglobin concentration during the first 2.5 hours after rtPA bolus. The
increases were faster and higher in the ipsilesional hemisphere. The results show that bedside
optical monitoring can detect the effect of reperfusion therapy for ischemic stroke in real-time.
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1. Introduction
In acute ischemic stroke (AIS) early reperfusion is a robust predictor of early recovery and
favorable functional outcome [1, 2]. In clinical practice, perfusion imaging with magnetic
resonance and computed tomography (CT) are increasingly used to triage patients for reperfusion
therapy, but, are rarely applied to assess its success due to the associated complexities such
as expense and the need to transport the patient. Therefore, the monitoring of the treatment
efficacy in AIS has focused primarily on the evidence of structural damage and arterial patency
rather than on microvascular cerebral blood flow (CBF) restoration. This is partly due to the
unavailability of monitoring techniques suitable for repeated microvascular CBF measurement
in the acute period. Instead, the recanalization of the occluded artery is frequently used as a
surrogate of reperfusion [3, 4]. However, although both are related and are often interchanged, it
is increasingly recognized that the recanalization does not necessarily lead to the reperfusion
of the distal region, and, contrarily, reperfusion can sometimes occur despite the persistence
of an occlusion [5]. The continuous quantification of microvascular hemodynamic changes, in
particular, microvascular CBF, with a noninvasive modality at early stages can improve our
understanding of the relationship between the reperfusion, recanalization and clinical recovery
due to interventions. It could also allow personalized treatment and management strategies.
Diffuse correlation spectroscopy (DCS) is an emerging method that measures local, microvas-
cular CBF noninvasively using near-infrared light [6]. DCS utilizes, noninvasive, near-infrared
light to track rapid temporal fluctuations of light intensity in brain tissue that arise when light is
scattered by moving red blood cells, which is then analyzed with a physical model to derive a
blood flow index.
Numerous validation studies have shown that the relative changes in CBF (∆rCBF) over
time measured by DCS agree with other techniques [7, 8]. DCS can be combined with near-
infrared diffuse optical spectroscopy (NIRS-DOS), a more established technique that uses
wavelength-dependent light attenuation to measure oxy-hemoglobin (HbO2), deoxy-hemoglobin
(Hb), and total hemoglobin concentration (THC) changes. Prior work has shown that this hybrid
DCS/NIRS-DOS optical monitor is capable of detecting cerebral hemodynamic changes [8, 9].
Previously, we have shown in a single-case report that DCS/NIRS-DOS measures correlated
with the recanalization of the middle cerebral artery (MCA) measured by transcranial Doppler
(TCD) during intravenous thrombolysis [10].
In this follow-up study, we aimed to confirm the feasibility of using DCS/NIRS-DOS as
a bedside method for real-time monitoring of local microvascular hemodynamic changes in
response to intravenous thrombolysis in a small case series of patients with AIS, and their
consistency with the recanalization and the clinical outcome.
2. Methods
2.1. Study design and participants
We have prospectively identified patients with an AIS admitted to the Emergency Department
within the first 4.5 hours from symptoms onset who were selected to be treated with intravenous
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thrombolysis. The protocol was approved by the local Ethics Committee (Hospital de la Santa
Creu i Sant Pau, EC/09/066/980). Inclusion criteria were: (1) a well-defined onset of symptoms
attributable to MCA territory ischemia affecting the frontal lobe (motor aphasia, contralesional
motor deficit or gaze deviation), (2) demonstration of MCA occlusion on angio-CT or TCD prior
to treatment with intravenous recombinant tissue plasminogen activator (rtPA), and (3) optical
monitoring being able to commence before or within the first fifteen minutes of the start of rtPA
infusion. We note that during the study period (2011-2012), mechanical thrombectomy was not
yet approved at our institution. Informed consent was obtained from the patients or their relatives.
Baseline examinations included a medical history (demographics and vascular risk factors)
and a physical examination. The stroke severity was assessed with the National Institutes of
Health Stroke Scale (NIHSS). Clinical outcome at three months was evaluated by means of the
modified Rankin Scale (mRS). A score >2 was considered indicative of an unfavorable outcome.
On admission, all patients underwent a cranial CT scan and vascular imaging either by
angio-CT or TCD before thrombolysis. Recanalization was assessed with TCD at 24 hours and,
in some cases, additionally during the rtPA perfusion according to the thrombolysis in brain
ischemia (TIBI) flow grade criteria, as previously described [11].
2.2. Optical methods and instrumentation
Optical monitoring was performed with a compact, user-friendly and portable hybrid instrument
of DCS and continuous-wave NIRS-DOS. The DCS consisted of a mode-hope free, long-
coherence-length, continuous-wave laser at 785 nm and eight single photon avalanche photodiode
detectors whose outputs were fed to a custom-built hardware autocorrelator. The continuous-wave
NIRS-DOS module consisted of two continuous-wave lasers at 690 and 830 nm and the diffuse
light from each was detected by the same detectors above. Optical switches were used to switch
the three measurement wavelengths (one for DCS, and two for NIRS-DOS) as well as the
measurements from the two cerebral hemispheres. This has allowed us to use continuous-wave
NIRS-DOS to evaluate the changes in HbO2 and Hb concentrations as well as microvascular
CBF. The output of four channels (four for each hemisphere) was averaged for each wavelength
for improving the signal-to-noise ratio.
Two optical probes were made of custom built fibers consisting of a source fiber and a detector
fiber bundle with four single-mode fibers with 2.5 cm source-detector separation. The use of 2.5
cm was justified by previous validation studies [7, 8] and by the increased sensitivity of DCS
to the brain blood flow [12]. The probes were placed bilaterally on the temporal margin of the
patient forehead superior to the frontal sinuses as shown in Fig. 1.
DCS monitors the light intensity fluctuations of the speckle patterns in order to calculate an
intensity autocorrelation function of this detected light. For this study, the reduced scattering
coefficient of the tissue at 785 nm was assumed to be constant (µ′s = 8.5 cm−1) [13]. The
continuous absorption coefficient (µa) changes at 785 nm from their baseline value (µa = 0.14
cm−1) [13] were measured by NIRS-DOS to improve the accuracy of the DCS measurements [8].
The intensity autocorrelation function from the autocorrelator was fitted using the correlation
diffusion equation (for a semi-infinite geometry) and also using the measured µa and µ′s obtaining
a continuous blood flow index (BFI) [6, 14]. The percent relative CBF change (∆rCBF) was
calculated from the BFI as∆rCBF = ((BFI/BFIbaseline)-1)*100, where BFIbaseline was calculated
from the cerebral BFI of the first five minutes of the recording.
A modified Beer-Lambert law [15] was used for the continuous-wave NIRS-DOS analysis
with the wavelengths 690 and 830 nm. The data was corrected for pathlength and partial volume
effects as explained in previous studies [15, 16]. Changes of oxy-hemoglobin (∆HbO2) and
deoxy-hemoglobin (∆Hb) concentrations were calculated as ∆HbO2(t)=HbO2(t)-HbO2 baseline
and ∆Hb(t)=Hb(t)-Hbbaseline. Again, the baseline was calculated from the first five minutes of
recording. Total hemoglobin concentration changes (∆THC) were then calculated as the sum of
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Fig. 1. The schematic of the source-detector separation of the optical probe (left). The
placement of the optical probes bilaterally on the forehead (right).
∆HbO2 and ∆Hb concentration changes. Data was collected from both hemispheres every 14.2 ±
5.7 (mean ± standard deviation) seconds.
2.3. Statistical analysis
The average baseline values for CBF, THC, HbO2 and Hb were obtained by averaging the
first five minutes of data, as mentioned, after fifteen minutes from rtPA bolus in each patient.
This was used to derive the changes of each variable relative to their baseline values at each
time point. The time interval between fifteen minutes from rtPA bolus up to hundred and fifty
minutes of monitoring (when available) was used for each patient. We have expressed quantitative
variables as a mean and a standard deviation (mean ± standard deviation) and analyzed the
data by performing linear mixed-effect models [17] for each individual patient and also for the
group. Linear mixed-effect models were needed due to the longitudinal nature of the data (lack
of independence of the response variable) when considering each patient independently. When
analyzing the patients as a group, these models were needed due to both the longitudinal nature of
the data and for correcting for the different patients in the group. The two types of analyses started
with a null model that included a continuous dependent variable (CBF, THC, HbO2 or Hb) for
each hemisphere (ipsilesional and contralesional). Patients (only when modeling as a group) and
time (when modeling as a group and also when considering each patient independently) were the
random factors. The predictor variable time was added to the null model as a fixed effect to see
whether this new model, with the predictor variable time, improved the null model. The model fit
was assessed using chi-square tests on the log-likelihood values to compare the new model versus
the null model. If the new model with the predictor variable time (1) improved over the null
model significantly, in other words, if the p value of the chi-square test between the two models
was <0.05, and (2) the null hypothesis stating that the slope of the new model was equal to zero
was rejected, the slope of this model would tell us about the time evolution (rate of increase or
decrease over time) of the continuous dependent variable. Residuals plots of this model were
tested for the inspection of deviations from normality or homoscedasticity. Instead, if the model
with the predictor variable time did not improve the null model significantly, the null hypothesis
stating that the slope of the new model was equal to zero was not rejected. Then, the continuous
dependent variable was considered constant over time (slope≈0). Wilcoxon rank-sum test was
used to assess the difference between the slopes of the two hemispheres with the alternative
hypothesis “ipsilesional change > contralesional change”. All analyses were carried out in the
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R programming language and environment [18] using the “nlme” software package. A p-value
<0.05 was considered to be statistically significant.
3. Results
During a 14-month period, we have identified thirteen patients who fulfilled the inclusion criteria.
Six were excluded due to late onset of the optical monitoring, mainly due to logistical reasons
(late arrival of trained personnel or late consent). Two were excluded due to technical problems
with the optical recording. Five patients (three female, mean age of 81 years) were finally included
in the analysis (Table 1).
The mean NIHSS score on admission was 19±3. MCA occlusion (four proximal, one distal)
was diagnosed by angio-CT in four patients and by TCD in one. The mean time from symptoms
onset to thrombolysis was 144±47 minutes. We note that the rtPA administration was not delayed
due to the study. All patients were hemodynamically stable and none received vasoactive drugs.
Fig. 2 illustrates the time course of ∆rCBF, ∆THC, ∆HbO2 and ∆Hb of all patients from
fifteen minutes of treatment onset in each hemisphere using linear mixed-effect models. The
slopes of the change of the optical variables as a function of time in both hemispheres for each
individual patient and also for the whole group are shown in Table 1. On a group basis, we
have found a statistically significant increase with time for frontal ipsilesional (p<0.001) and
contralesional (p=0.018) ∆rCBF, for ipsilesional (p<0.001) and contralesional (p=0.014) ∆THC
and for ipsilesional and contralesional ∆HbO2 (both p<0.001). On the other hand, ∆Hb did not
change significantly in any hemisphere. We have observed an asymmetrical time evolution of the
optical variables between hemispheres. A statistically significant faster increase (greater slope)
was observed in the affected hemisphere for ∆rCBF (p=0.031), ∆THC (p=0.032) and ∆HbO2
(p=0.030) compared to the contralesional hemisphere.
At 24 hours, all patients improved by eight or more points in the NIHSS score. Complete
arterial recanalization was documented in all but one patient (due to insufficient acoustic window)
at 24 hours. In two patients recanalization was also documented at thirty minutes and at the end
of rtPA infusion by continuous TCD.
At three month-follow up, four out of five patients were functionally independent (mRS<3),
and one had moderate disability (mRS=3).
4. Discussion
In this pilot study, DCS/NIRS-DOS was able to be deployed at the bedside without any effects
on the clinical treatment. On a group basis, it detected an increase in frontal CBF, THC, and
HbO2 in both hemispheres which was significantly faster in the ipsilesional side in a series of
AIS patients with a clinical improvement after rtPA-associated recanalization. We were able
to obtain real-time optical data in five out of thirteen (38%) patients who fulfilled the clinical
criteria. The reasons of exclusion were related to the logistics and technical reasons. Although
the feasibility of its application in the clinical setting with the current set-up appeared limited
(see below), these results support the potential role of diffuse optical technology for continuous
cerebral perfusion monitoring during therapeutic interventions in patients with AIS.
Currently, TCD is the only available tool for routine clinical use for the noninvasive and
real-time monitoring of cerebral hemodynamics after reperfusion therapy [19]. TCD measures
blood flow velocities in the major intracranial arteries, which correlates with CBF only as long as
the vessel diameter remains constant [20]. Its main limitations are that it is operator dependent
and requires training and experience to perform and interpret the results [19]. Also, an insufficient
acoustic bone window limits its application in 20% to 30% of the patients [21]. Furthermore,
TCD can directly insonate only proximal vascular segments of large arteries and only indirectly
provides information about more distal vascularity [22]. Therefore, TCD is suitable for the
monitoring of the large artery recanalization, but not for the microcirculatory reperfusion.
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Table 1. Clinical and optical variables for each individual patient and also for the group.
Case 1 2 3 4 5 All
Age (y), Sex(M/F) 80, F 58, M 93, F 80, M 92, F 81±14
Arterial occlusion
Left
MCA
(distal)
Right
MCA
(prox.)
Left
MCA
(prox.)
Right
MCA
(prox.)
Right
MCA
(prox.)
NIHSS
Pre
rtPA 15 16 22 21 19 19±3
Post
rtPA - 14 5 13 9 10±4
24h 3 8 2 4 1 4±3
Recanalization Unkn. Yes Yes Yes Yes
mRS 90 days 1 2 3 1 1 2±1
Slope
of
the
linear
model
∆rCBF(
%
min
) Ipsiside 0.17† 0.54† 0.45† 0.23† 0.023 0.29†‡
Cont.
side 0.085 0.33† 0.32† 0.013 -0.00080 0.16†
∆THC(
µM
min
) Ipsiside 0.023† 0.035† 0.063† 0.030† 0.0055† 0.041†‡
Cont.
side -0.0051 0.0023 0.030† 0.029† 0.041† 0.019†
∆HbO2(
µM
min
) Ipsiside 0.046† 0.053† 0.059† 0.026† 0.050† 0.047†‡
Cont.
side 0.00060 0.026† 0.031† 0.019† 0.047† 0.025†
∆Hb(
µM
min
) Ipsiside -0.023† -0.018† 0.0031† 0.0042† 0.0050 -0.0056
Cont.
side -0.0057 -0.024† -0.0015 0.010† -0.0063† -0.0053
(∆) indicates a change of each optical variable from the baseline (within fifteen minutes from rtPA
bolus) to the end of the monitoring (∼2.5 hours). (†) indicates a statistically significant slope. (‡)
indicates a statistically significant difference between ipsi- over contra-lesional side as a group.
M=male. F= female. NIHSS=National Institutes of Health Stroke Scale. mRS=modified Rankin
scale. rCBF=relative cerebral blood flow. THC=total hemoglobin concentration. HbO2=oxy-
hemoglobin. Hb=deoxy-hemoglobin. Ipsi=ipsilesional. Cont.=contralesional. Prox.=proximal.
Unkn.=unknown. Mean ± standard deviation.
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Fig. 2. Frontal microvascular relative cerebral blood flow (rCBF), total hemoglobin concen-
tration (THC), oxy-hemoglobin (HbO2), and deoxy-hemoglobin (Hb) changes over time
are shown for the ipsilesional hemisphere (left column) and the contralesional hemisphere
(right column) for all five patients (each patient in different color). (∆) indicates a change
of the optical variable from the baseline. Black line shows the fitted linear model of all
the measurement points plotted. The time, x-axis, shows the time elapsed from the rtPA
treatment onset. (*) indicates a statistically significant positive slope (p<0.05).
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In contrast, diffuse optical methods provide real time information of the microvascular CBF
and microvascular blood oxygenation. Diffuse optical instrumentation is in general portable
and, in principle, can be easy to apply without the need of extended technical expertise [8, 23].
Despite this, the clinical application of diffuse optical techniques in the context of cerebrovascular
disease is limited. Many reasons can be speculated, including the concern about the potential
contamination of the signal by superficial tissues, the problems of motion artifacts and its limited
spatial resolution. This is bound to change since more advanced instrumentation and algorithms
are being introduced.
Previously, anecdotal studies of single case reports or small series have evaluated the yield of
NIRS-DOS-based cerebral oximetry to estimate the adequacy of cerebral perfusion in AIS [24–26].
Recently, Hametner et al. reported a larger series of sixty-three patientsmonitoredwith commercial
NIRS-DOS during mechanical thrombectomy, of whom forty-three had valid data [27]. During
the procedure, regional oxygen saturation peaks were observed in fourteen (32.6%) patients and
a sustained increase after recanalization in only two patients (4.7%). Although some regional
oxygen saturation indices were reported to be associated with the reperfusion status and clinical
outcome, the authors concluded that the ability of the current commercial NIRS-DOS monitors to
probe local reperfusion is limited. Others have used indocyanine green as a tracer to demonstrate
CBF reductions with NIRS-DOS in patients with AIS, showing a good correlation with perfusion
weighted imaging measurements [25, 28]. However, the need of an exogenous contrast agent
limits their use for continuous monitoring purposes.
Previous studies have shown that DCS can successfully track autoregulatory changes of CBF
without the need of contrast agents in patients with cerebrovascular disease by using vasoactive
stimuli [29,30]. In this report, we have described a real-time sustained ∆rCBF increase measured
by DCS after intravenous thrombolysis. DCS-derived ∆rCBF measures were in agreement with
the simultaneously NIRS-DOS-measured THC and HbO2, as we have previously suggested in
a single case report [10]. Furthermore, DCS parameters showed a different response between
the ipsilesional and contralesional hemispheres in agreement with NIRS-DOS, demonstrating
the potential of DCS to detect early changes in cerebral perfusion caused by the rtPA treatment.
This asymmetric response found between both hemispheres also adjusts for possible systemic
circulatory or respiratory disorders as potential confounders.
The main difference of DCS over NIRS-DOS is that it provides a direct measure of cerebral
perfusion, which is the goal of most interventions in AIS. In contrast, NIRS-DOS is used as an
indirect measure of cerebral perfusion based on changes in blood oxygenation or volume which
has been shown to differ from CBF in brain-injured patients [31]. Furthermore, the combination of
both techniques can be used to assess the cerebral metabolic rate of oxygen extraction (CMRO2),
a potentially sensitive biomarker of brain injury [8, 32]. Thus, the combination of DCS and
NIRS-DOS offers a more complete view of brain health than any of the techniques alone.
The increase in CBF during thrombolysis may reflect the restoration of downstream flow not
only by the recanalization of the occluded artery, but also by the increase of collateral circulation.
We have documented arterial recanalization on TCD in four patients at 24 hours. In two of them,
by using continuous TCD monitoring, we have showed that the arterial recanalization coincided
with CBF increase during rtPA infusion. We note that leptomeningeal collateral flow may also
contribute to cortical CBF changes detected by DCS, as suggested by previous studies, in which
CBF variations correlated with changes in MCA velocities on TCD in healthy volunteers but
diverged in patients with severe carotid artery stenosis who had activated compensatory flow
sources [30, 33]. Unfortunately, our neuroimaging protocol did not include the assessment of the
collateral circulation to support this hypothesis in order to avoid delays in the administration of
intravenous rtPA.
Our report has some limitations including the availability of only relative data, the small number
of patients recruited and the lack of a control group (patients without recanalization). Instead,
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we have used the contralesional hemisphere as a control. The recent emergence of commercial
hybrid systems (e.g. HemoPhotonics S.L. and ISS) and European projects (BabyLux [34]) where
user-friendly neuromonitors combining both methods have been developed should allow us to
increase the yield of transcranial optical monitoring in the clinical settings which was lacking
in our case. Moreover, the use of time resolved methods (e.g. in Babylux) should allow for
absolute measurements even in the adult head [35]. Due to the small number of subjects in
this proof-of-concept study, we have avoided a discussion of each individual’s data. Also, our
measurements were limited to one single location in the forehead. We could have measured on
different cortical areas; however, we prioritized simplicity to avoid delays on the treatment. As
with other modalities based on diffuse light in the near-infrared, DCS has a relatively poor spatial
resolution and the light penetration depth is restricted to a few millimeters of the superficial
cortex (total depth of penetration of ∼1.5 cm). Also, diffuse optical spectroscopy techniques
measure information from the brain, but also contain scalp and skull contributions [8, 35]. In this
work, instead of including also a small source-detector separation (∼1 cm) to study the superficial
effects, we chose to keep all eight detectors (four for each side) for large separations to focus on
the signal-to-noise ratio. However, a source-detector separation of 2.5 cm is a good compromise
as shown by other earlier studies [7, 8, 12]. Future implementations could utilize more source-
detector pairs and pressure modulation [36]. Finally, DCS results show a higher relative noise
than NIRS-DOS results which is well known with the current technology. This is partly remedied
since the increased contrast in CBF amounts to a comparable contrast-to-noise-ratio [12].
5. Conclusion
In conclusion,we have shown that continuous diffuse opticalmonitoring of cerebral hemodynamics
at the bedside in AIS patients treated with intravenous thrombolysis is feasible. Our study supports
further research in larger populations with the emerging improved set-ups of optical technology
for the clinical environment.
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